OLICERIDINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for oliceridine and what is the scope of freedom to operate?
Oliceridine
is the generic ingredient in one branded drug marketed by Trevena and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Oliceridine has fifty-one patent family members in twenty-three countries.
One supplier is listed for this compound.
Summary for OLICERIDINE
| International Patents: | 51 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Clinical Trials: | 5 |
| Patent Applications: | 97 |
| What excipients (inactive ingredients) are in OLICERIDINE? | OLICERIDINE excipients list |
| DailyMed Link: | OLICERIDINE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OLICERIDINE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OLICERIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Tennessee | Phase 4 |
| Trevena Inc. | Phase 4 |
| The Cleveland Clinic | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for OLICERIDINE
US Patents and Regulatory Information for OLICERIDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OLICERIDINE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 2688403 | ⤷ Sign Up | |
| Eurasian Patent Organization | 025456 | ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) | ⤷ Sign Up |
| Hong Kong | 1250984 | 阿片樣物質受體配體以及使用和製備其的方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) | ⤷ Sign Up |
| Japan | 5912169 | ⤷ Sign Up | |
| Denmark | 3290415 | ⤷ Sign Up | |
| European Patent Office | 2688403 | LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) | ⤷ Sign Up |
| South Korea | 20140047599 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
